Researcher looking through microscope

Kestra Medical Publishes ASSURE Defibrillator Study Showing 100% Conversion of Analyzable Shock Events

Kestra Medical Technologies (NASDAQ:KMTS) announced the publication of primary results from its ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology, reporting that its wearable defibrillator successfully converted all 303 analyzable ventricular arrhythmia shock events recorded during the study.

The prospective, FDA-mandated post-approval study evaluated the safety and effectiveness of the company’s ASSURE Wearable Cardioverter Defibrillator (WCD) in routine clinical practice.

The registry enrolled 21,612 patients across 35 US states between November 2021 and July 2025, making it a large-scale assessment of the device’s performance outside a controlled clinical trial setting.

Kestra reported that the study met both of its prespecified primary endpoints for shock conversion effectiveness and inappropriate-shock safety.

ASSURE Device Meets Primary Effectiveness and Safety Endpoints

The study assessed the ASSURE device’s ability to treat ventricular tachycardia and ventricular fibrillation (VT/VF), potentially life-threatening heart rhythm disturbances that can require electrical defibrillation.

According to the published results, the device successfully converted all 303 analyzable VT/VF shock events, representing a 100% all-shock conversion rate within the evaluated events.

The study also reported an inappropriate-shock rate of 0.0065 per patient-month, meeting its predefined safety performance objective.

Inappropriate shocks occur when a defibrillator delivers treatment in circumstances where a shock is not clinically required.

The results reflect the device’s performance among patients enrolled in the post-approval registry and should be interpreted within the study’s observational design.

Patients Recorded Median Daily Wear Time of 23.1 Hours

The study also examined how consistently patients used the wearable defibrillator during their prescribed treatment periods.

Median daily wear time was 23.1 hours, indicating that patients typically wore the device for most of each day.

Approximately 30% of participants continued using the device beyond 90 days, maintaining the same median daily wear time.

Among enrolled patients, 94% did not experience any false-positive shock alarms during the study.

The findings provide information about device usage patterns and alarm performance during routine clinical care.

Ventricular Arrhythmia Events Continued Beyond First Month

The registry also evaluated the timing and frequency of ventricular tachycardia and ventricular fibrillation episodes among patients using the ASSURE device.

A total of 2.6% of enrolled patients experienced at least one VT/VF event.

Of the recorded episodes, 55% occurred during the first month of device use, although additional events were observed in subsequent months.

The study also estimated the 90-day risk of VT/VF among patients with left ventricular ejection fraction of 35% or less who met primary-prevention criteria for sudden cardiac death.

For patients following a myocardial infarction, the estimated risk was 3.2%.

The corresponding estimates were 2.8% for patients with ischemic cardiomyopathy and 2.5% for those with nonischemic cardiomyopathy.

These findings provide additional information about the occurrence of ventricular arrhythmias among patients considered at risk of sudden cardiac death.

Jeanne E. Poole, MD, Professor of Medicine at the University of Washington and principal investigator of the study, commented on the findings.

“ACE-PAS confirmed the early risk of ventricular tachycardia and ventricular fibrillation and demonstrates why WCD protection matters,” Poole said.

Updated Detection Algorithm Expected to Reduce Inappropriate Shocks

Kestra also provided information about an enhanced detection algorithm introduced for the ASSURE device in April 2026.

The company projects that the updated algorithm could reduce the inappropriate-shock rate by nearly 70%, from the study’s reported 0.0065 per patient-month to approximately 0.0020 per patient-month.

The projected reduction is based on the company’s assessment of the enhanced algorithm and is separate from the primary clinical results reported in the ACE-PAS publication.

The company did not report new prospective clinical outcomes confirming that projected reduction in the information provided.

Results Follow Initial Presentation at AHA Scientific Sessions

The ACE-PAS findings were initially presented at the American Heart Association Scientific Sessions in 2025 before their subsequent publication in the Journal of Cardiovascular Electrophysiology.

The study was funded by Kestra Medical Technologies.

The publication provides additional clinical information on the ASSURE wearable defibrillator’s shock conversion performance, inappropriate-shock frequency, patient adherence and the timing of ventricular arrhythmia events.

As a prospective post-approval registry, the study evaluated the device during routine clinical use rather than through a randomised comparison with another treatment.

Kestra Medical Technologies stock price


Posted

in

by

Tags: